Trial · NCT05022563
Participant flow30
How many started, completed or left each group, period by period.
1 to 20 of 30
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Warfarin-Based Therapy | 11,208 | |
| Overall Study | STARTED | Non-vitamin K Antagonist Oral Anticoagulants (NOAC)-Based Therapy: Apixaban | 5,047 | |
| Overall Study | STARTED | NOAC-Based Therapy: Dabigatran | 2,103 | |
| Overall Study | STARTED | NOAC-Based Therapy: Edoxaban | 2,342 | |
| Overall Study | STARTED | NOAC-Based Therapy: Rivaroxaban | 26,276 | |
| Overall Study | STARTED | Parenteral Anticoagulants (PAC) Only | 8,783 | |
| Overall Study | Without Active Cancer | Warfarin-Based Therapy | 10,390 | |
| Overall Study | Without Active Cancer | Non-vitamin K Antagonist Oral Anticoagulants (NOAC)-Based Therapy: Apixaban | 4,543 | |
| Overall Study | Without Active Cancer | NOAC-Based Therapy: Dabigatran | 1,894 | |
| Overall Study | Without Active Cancer | NOAC-Based Therapy: Edoxaban | 2,078 | |
| Overall Study | Without Active Cancer | NOAC-Based Therapy: Rivaroxaban | 23,049 | |
| Overall Study | Without Active Cancer | Parenteral Anticoagulants (PAC) Only | 6,550 | |
| Overall Study | With Active Cancer (Diagnosis of Cancer Within Past 6 Months of Index Date) | Warfarin-Based Therapy | 818 | |
| Overall Study | With Active Cancer (Diagnosis of Cancer Within Past 6 Months of Index Date) | Non-vitamin K Antagonist Oral Anticoagulants (NOAC)-Based Therapy: Apixaban | 504 | |
| Overall Study | With Active Cancer (Diagnosis of Cancer Within Past 6 Months of Index Date) | NOAC-Based Therapy: Dabigatran | 209 | |
| Overall Study | With Active Cancer (Diagnosis of Cancer Within Past 6 Months of Index Date) | NOAC-Based Therapy: Edoxaban | 264 | |
| Overall Study | With Active Cancer (Diagnosis of Cancer Within Past 6 Months of Index Date) | NOAC-Based Therapy: Rivaroxaban | 3,227 | |
| Overall Study | With Active Cancer (Diagnosis of Cancer Within Past 6 Months of Index Date) | Parenteral Anticoagulants (PAC) Only | 2,233 | |
| Overall Study | COMPLETED | Warfarin-Based Therapy | 11,208 | |
| Overall Study | COMPLETED | Non-vitamin K Antagonist Oral Anticoagulants (NOAC)-Based Therapy: Apixaban | 5,047 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05022563/flow